Insider Trading Activity ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – EVP Sold 14,322 shares of Stock

Insider Trading Activity For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Glenn Baity , EVP of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reportedly Sold 14,322 shares of the company’s stock at an average price of 34.88 for a total transaction amount of $499,551.36 SEC Form

Insider Trading History For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

On 4/11/2013 Thomas H Aasen, CFO, sold 40,000 with an average share price of $11.06 per share and the total transaction amounting to $442,400.00.View SEC Filing

On 4/12/2013 Glenn Baity, VP, sold 60,000 with an average share price of $12.42 per share and the total transaction amounting to $745,200.00.View SEC Filing

On 5/15/2013 Felix Baker, Director, bought 1,993,000 with an average share price of $12.50 per share and the total transaction amounting to $24,912,500.00.View SEC Filing

On 6/5/2013 Felix Baker, Director, bought 2,340,314 with an average share price of $14.34 per share and the total transaction amounting to $33,560,102.76.View SEC Filing

On 8/13/2013 Uli Hacksell, CEO, sold 52,771 with an average share price of $20.14 per share and the total transaction amounting to $1,062,807.94.View SEC Filing

On 8/13/2013 Thomas Aasen, CFO, sold 60,000 with an average share price of $20.15 per share and the total transaction amounting to $1,209,000.00.View SEC Filing

On 8/26/2013 Mary Ann Gray, Director, sold 15,000 with an average share price of $20.68 per share and the total transaction amounting to $310,200.00.View SEC Filing

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
These are 3 Hold Ratings, 9 Buy Ratings .
The current consensus rating for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy (Score: 2.75) with a consensus target price of $44.17 , a potential (41.51% upside)

Analyst Ratings History For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

• On 8/5/2016 Aegis Downgraded rating Buy to Hold with a price target of $54.00 to $41.00
• On 8/10/2016 JMP Securities Reiterated Rating Buy with a price target of $45.00
• On 10/19/2016 Roth Capital Reiterated Rating Neutral with a price target of $25.00
• On 11/8/2016 Bank of America Corporation Upgraded rating Neutral to Buy with a price target of $35.00
• On 11/11/2016 Goldman Sachs Group, Inc. (The) Initiated Coverage of rating Neutral with a price target of $28.00
• On 12/28/2016 Leerink Swann Reiterated Rating Market Perform with a price target of $29.00
• On 1/11/2017 J P Morgan Chase & Co Reiterated Rating Buy

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 31.21 up +0.98 3.24% with 2,074,087 shares trading hands.